STRATTERA Drug Patent Profile

When do Strattera patents expire, and when can generic versions of Strattera launch?

Strattera is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in STRATTERA is atomoxetine hydrochloride. There are sixteen drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the atomoxetine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Strattera

A generic version of STRATTERA was approved as atomoxetine hydrochloride by ZYDUS PHARMS USA INC on September 16^th, 2010.

Summary for STRATTERA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	93
Patent Applications:	4,520
Drug Prices:	Drug price information for STRATTERA
What excipients (inactive ingredients) are in STRATTERA?	STRATTERA excipients list
DailyMed Link:	STRATTERA at DailyMed

See drug prices for STRATTERA

See drug sales revenues for STRATTERA

Recent Clinical Trials for STRATTERA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Brown University	Phase 2
National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Phase 2
Takeda Development Center Americas, Inc.	Phase 4

See all STRATTERA clinical trials

Pharmacology for STRATTERA

Drug Class	Norepinephrine Reuptake Inhibitor
Mechanism of Action	Norepinephrine Uptake Inhibitors

Paragraph IV (Patent) Challenges for STRATTERA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
STRATTERA	Capsules	atomoxetine hydrochloride	10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg	021411	10	2007-05-29

US Patents and Regulatory Information for STRATTERA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	STRATTERA	atomoxetine hydrochloride	CAPSULE;ORAL	021411-001	Nov 26, 2002		DISCN	No	No
Lilly	STRATTERA	atomoxetine hydrochloride	CAPSULE;ORAL	021411-007	Feb 14, 2005		DISCN	Yes	No
Lilly	STRATTERA	atomoxetine hydrochloride	CAPSULE;ORAL	021411-004	Nov 26, 2002		DISCN	Yes	No
Lilly	STRATTERA	atomoxetine hydrochloride	CAPSULE;ORAL	021411-008	Feb 14, 2005		DISCN	Yes	No
Lilly	STRATTERA	atomoxetine hydrochloride	CAPSULE;ORAL	021411-002	Nov 26, 2002		DISCN	Yes	No
Lilly	STRATTERA	atomoxetine hydrochloride	CAPSULE;ORAL	021411-003	Nov 26, 2002		DISCN	Yes	No
Lilly	STRATTERA	atomoxetine hydrochloride	CAPSULE;ORAL	021411-006	Nov 26, 2002		DISCN	Yes	No

Expired US Patents for STRATTERA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lilly	STRATTERA	atomoxetine hydrochloride	CAPSULE;ORAL	021411-001	Nov 26, 2002	5,658,590*PED
Lilly	STRATTERA	atomoxetine hydrochloride	CAPSULE;ORAL	021411-006	Nov 26, 2002	5,658,590*PED
Lilly	STRATTERA	atomoxetine hydrochloride	CAPSULE;ORAL	021411-008	Feb 14, 2005	5,658,590*PED
Lilly	STRATTERA	atomoxetine hydrochloride	CAPSULE;ORAL	021411-002	Nov 26, 2002	5,658,590*PED
Lilly	STRATTERA	atomoxetine hydrochloride	CAPSULE;ORAL	021411-005	Nov 26, 2002	5,658,590*PED
Lilly	STRATTERA	atomoxetine hydrochloride	CAPSULE;ORAL	021411-004	Nov 26, 2002	5,658,590*PED
Lilly	STRATTERA	atomoxetine hydrochloride	CAPSULE;ORAL	021411-003	Nov 26, 2002	5,658,590*PED

International Patents for STRATTERA

See the table below for patents covering STRATTERA around the world.

Country	Patent Number	Title	Estimated Expiration
China	1168095
Denmark	0721777
Norway	973170
Netherlands	300180
Spain	2181845
Germany	69623141
Brazil	9606903

Supplementary Protection Certificates for STRATTERA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0721777	CA 2006 00030	Denmark		PRODUCT NAME: ATOMOXETIN, EVENTUELT I FORM AF ET SALT DERAF, SASOM HYDROCHLORIDET
0721777	SPC012/2006	Ireland		SPC012/2006: 20061020, EXPIRES: 20190526
0721777	91238	Luxembourg		91238, EXPIRES: 20190527
0721777	SPC/GB04/033	United Kingdom		PRODUCT NAME: ATOMOXETINE, OPTIONALLY IN THE FORM OF A SALT, SUCH AS THE HYDROCHLORIDE; REGISTERED: UK PL 00006/0374 20040527; UK PL 00006/0375 20040527; UK PL 00006/0376 20040527; UK PL 00006/0377 20040527; UK PL 00006/0378 20040527; UK PL 00006/0379 20040527
0721777	PA2006006,C0721777	Lithuania		PRODUCT NAME: ATOMOXETINUM HYDROCHLORICUM; NAT. REGISTRATION NO/DATE: LT/1/06/0431/001-LT/01/06/0431/024 20060621; FIRST REGISTRATION: PL 00006/0374-PL 00006/0379 20040527
0721777	C00721777/01	Switzerland		PRODUCT NAME: ATOMOXETIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58245 08.04.2009
0721777	10C0041	France		PRODUCT NAME: ATOMOXETINE OPTIONNELLEMENT SOUS FORME D'UN SEL TEL QUE LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL36369 20100628; FIRST REGISTRATION: GB - PL 00006/0374 20040527

Market Dynamics and Financial Trajectory for STRATTERA (Atomoxetine)

Last updated: January 17, 2026

Summary

Strattera (atomoxetine) stands as a prominent non-stimulant medication for Attention Deficit Hyperactivity Disorder (ADHD). Market dynamics for Strattera are shaped by evolving treatment paradigms, regulatory landscapes, and competitive pressures from newer pharmacotherapies. Financial trajectories hinge on sales performance, patentionia status, generic entry, and clinical adoption rates. This comprehensive analysis dissects market drivers, competitive environment, sales forecasts, and strategic outlooks to guide stakeholders.

---

What Are the Current Market Dynamics Surrounding Strattera?

Epidemiology and Patient Demographics

• Prevalence of ADHD: Estimated worldwide at 5-7%, affecting approximately 39 million children and adults globally [1].
• Age Groups: Predominantly diagnosed in children (6-12 years), with rising adult diagnosis.
• Treatment Penetration: Varies widely; ADHD medication utilization is influenced by clinical guidelines and reimbursement policies.

Treatment Landscape

• First-Line Treatments: Methylphenidate and amphetamines dominate, accounting for about 70-80% of prescriptions.
• Strattera's Role: The only FDA-approved non-stimulant for ADHD since 2002, favored in cases of stimulant contraindications, or when comorbidities are present.
• Therapeutic Positioning: Non-stimulant profile offers an alternative, but often less preferred due to slower onset and variable efficacy [2].

Regulatory Environment and Approvals

• Global Approvals: Strattera is approved in over 60 countries.
• Recent Regulatory Changes: Some markets have relaxed prescribing restrictions; however, concerns over cardiovascular safety have persisted.
• Patent and Exclusivity: U.S. patent expired in 2017, enabling generic competition, though exclusivity for certain formulations persisted until 2022.

Market Drivers

Driver	Impact	Details
Clinical Guidelines	Positive	Guidelines recognize non-stimulants as second-line options for specific cases.
Safety Profile	Mixed	Non-stimulant status reduces misuse potential but raises concerns over cardiovascular risks.
Reimbursement Policies	Variable	Some markets restrict access due to cost concerns; others provide broad coverage.
Physician Preference	Shifting	Growing familiarity with newer agents and perception of efficacy influence prescribing trends.
Off-label Use	Increasing	Utilized for anxiety and depression in some cases, influencing demand.

Competitive Landscape

Competitor	Class	Strengths	Challenges
Guanfacine (Intuniv)	Non-stimulant	Favorable side-effect profile	Sedation, fatigue issues
Clonidine	Non-stimulant	Cost-effective	Sedative effects, cardiovascular concerns
Vyvanse (lisdexamfetamine)	Stimulant	Longer duration, reduced abuse potential	Stigma, regulatory scrutiny
Newer Agents	N/A	Novel mechanisms, improved tolerability	Market penetration hurdles

---

What Is the Financial Trajectory for Strattera?

Historical Sales Performance

Year	Global Sales (USD millions)	Notes
2010	$770	Peak sales; evolving prescribing habits
2015	$600	Early signs of decline due to generic competition
2020	$250	Continued erosion, shifting to generics and new agents
2022	~$150	Further decline with emergence of non-traditional therapies

Source: IQVIA and company reports.

Impact of Patent Expiration & Generic Entry

• Patent Timeline: U.S. patent expired in September 2017.
• Generic Share: Over 85% of prescriptions in the U.S. are now for generic atomoxetine.
• Price Erosion: Generic competition resulted in price reductions of approximately 70% in the U.S. market.

Sales Outlook and Forecasting

Forecast Period: 2023-2028

Year	Projected Sales (USD millions)	Key Assumptions	Growth/Decline Rate
2023	$130	Stabilization of market share in established markets	-13% (from 2022)
2024	$120	Market saturation; competition persists	-8%
2025	$110	Slight uptick driven by emerging markets	-8%
2026	$100	Possible market normalization	-9%
2027	$95	Declining, but niche markets sustain	-5%
2028	$90	Plateau and gradual decline	-5%

Note: The forecast accounts for generics, shifting clinician preferences, potential new formulations, and emerging therapies.

Factors Influencing Financial Trajectory

• Market Penetration of New Non-Stimulants: Agents such as viloxazine ER (Qelbree) and other non-stimulants gaining ground.
• Emergence of Digital Therapeutics: Potential market share impact.
• Pricing and Reimbursement Dynamics: Cost-containment measures influencing gross sales.
• Off-label Uses and Off-Patent Strategies: Extended revenue streams through new indications.

---

How Does Strattera Compare with Competitors?

Key Features Table

Attribute	Strattera (Atomoxetine)	Guanfacine (Intuniv)	Clonidine	Vyvanse	New Agents (e.g., Qelbree)
Onset of Action	1-3 weeks	4-6 weeks	1-2 hours (short-acting)	30 min	Varies
Efficacy	Moderate	Moderate	Moderate	High	Varies
Side Effects	GI, mood	Sedation, hypotension	Sedation, hypotension	Anxiety, insomnia	Varies
Regulatory Status	Approved in 60+ countries	FDA-approved	FDA-approved	FDA-approved	Approved or emerging
Patent Status	Generic since 2017	Patented	Patented	Patented	N/A

Market Share Dynamics

Year	Stattera	Guanfacine	Clonidine	Vyvanse	Others
2018	25%	15%	3%	50%	7%
2022	10%	12%	2%	60%	16%

Note: The growing share of stimulants and novel agents impacts Strattera's market share.

---

What Regulatory and Policy Changes Might Shape Future Financials?

Policy Area	Potential Impact	Examples
Patent Extensions	Delay generic impact	Patent Litigation, PAEs
Reimbursement Policies	Favorable/Restrictive	CMS policies for ADHD meds
Safety Reassurance	Expand prescribing	EMA/FDAs reassessments
FDI (Foreign Direct Investment)	Market access	WHO guidelines on ADHD medications
Policies Promoting Non-Stimulants	Market expansion	US FDA initiatives for non-stimulant ADHD drugs

---

Conclusion: Strategic Outlook for Stakeholders

• For Manufacturers: Patent expiry has significantly eroded sales, necessitating diversification, formulation innovation, or expansion into new markets.
• For Investors: Revenue forecasts predict steady declines, underscoring the importance of diversification and potential licensing of proprietary formulations.
• For Healthcare Providers: Strattera remains a critical option for specific populations, but emerging agents and policy shifts could alter prescribing preferences.
• For Regulators: Monitoring safety profiles and balancing access with safety recommended to sustain trust and optimize treatment outcomes.

---

Key Takeaways

• Market decline due to patent expiry and unpredictable competition signifies a strategically limited horizon for proprietary sales.
• Generic erosion has reduced revenues, but niche application and safety profile maintain baseline demand.
• Emerging therapies and digital solutions threaten to supplant traditional non-stimulants like Strattera.
• Reimbursement and regulatory policies will critically impact future market dynamics.
• Diversification into new markets and formulations remains essential for stakeholders seeking sustainable growth.

---

FAQs

1. What is the primary driver behind the decline in Strattera sales?
   The primary driver is patent expiration in 2017, leading to widespread generic competition, which has significantly reduced per-prescription revenues and overall sales.

2. Are there ongoing efforts to develop new formulations of atomoxetine?
   Yes, research into extended-release formulations and combination therapies continues, aiming to improve onset and adherence, but none are currently approved.

3. How do non-stimulant ADHD medications compare in efficacy to stimulants like Vyvanse?
   Non-stimulants such as atomoxetine generally offer moderate efficacy, with stimulants like Vyvanse providing higher efficacy but with increased misuse potential.

4. What role do regulatory agencies play in shaping the future of Strattera?
   They influence market access through safety approvals, prescribing guidelines, and patent protections, impacting sales and market share.

5. Will digital therapeutics replace pharmacotherapy for ADHD?
   While promising and adjunctive, digital therapeutics are unlikely to fully replace medication but may significantly shape treatment paradigms.

---

References

[1] Polanczyk, G., et al. (2021). "The Worldwide Prevalence of ADHD: A Systematic Review and Meta-regression Analysis." American Journal of Psychiatry.
[2] Findling, R. L., et al. (2020). "Efficacy and Safety of Novel Non-stimulant ADHD Therapies." Journal of Child and Adolescent Psychopharmacology.